2'-fluoro-2'-deoxyadenosine profile

2'-fluoro-2'-deoxyadenosine, also known as F-dAdo, is a synthetic nucleoside analog that has shown promise as an antiviral and anticancer agent. It is synthesized by fluorination of 2'-deoxyadenosine. F-dAdo acts as an inhibitor of viral DNA polymerases, including those of HIV, herpes simplex virus, and cytomegalovirus. It has also shown activity against certain types of cancer cells, including leukemia and lymphoma. F-dAdo is studied because of its potential therapeutic applications in the treatment of viral infections and cancer. Research on F-dAdo focuses on understanding its mechanism of action, improving its pharmacokinetic properties, and exploring its therapeutic potential in various disease models.

ID Source	ID
PubMed CID	100253
CHEMBL ID	309579
SCHEMBL ID	237404
MeSH ID	M0097658

Synonym
CHEMBL309579 ,
2'-beta-fluoro-2',3'-deoxyadenosine
(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol
64183-27-3
2'-deoxy-2'-fluoroadenosine
2'f-da
9-(2-fluoro-2-deoxy-beta-d-ribofuranosyl)-purin-6-amine
bdbm50144932
(2r,3r,4r,5r)-4-fluoro-2-hydroxymethyl-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-3-ol
(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
2'-fluoro-2'-deoxyadenosine
nsc 274941
adenosine, 2'-deoxy-2'-fluoro-
(2r,3r,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol
AKOS015900907
HG1028
SCHEMBL237404
6-amino-9-(2-deoxy-2-fluoro-beta-d-ribofuranosyl)-9h-purine
ZGYYPTJWJBEXBC-QYYRPYCUSA-N
9-(2-deoxy-2-fluoro-beta-d-ribofuranosyl)adenine
c10h12fn5o3
mfcd09750859
2 inverted exclamation marka-deoxy-2 inverted exclamation marka-fluoroadenosine
CS-0097284
AC-9552
2-fluoro-2-deoxyadenosine
AS-49376
DTXSID60982712
AMY31026
A851108
HY-W039442
PD158370
BP-58852

Excerpt	Relevance	Reference
" The sensitivity of CLL cells to nine drugs (2'-chlorodeoxyadenosine, cisplatin, chlorambucil, cyclosporin A, doxorubicin, fludarabine, prednisolone, verapamil and vincristine) and two types of irradiation (gamma and UV-irradiation) was determined from dose-response curves of 4-day cultures ex vivo."	( CD80 antigen expression as a predictor of ex vivo chemosensitivity in chronic lymphocytic leukemia. Hulkkonen, J; Hurme, M; Kivekäs, I; Vilpo, J; Vilpo, L, 2002)	0.31

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RNA-directed RNA polymerase		IC50 (µMol)	50.0000	0.0190	2.5279	8.8000	AID86858
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histamine H1 receptor	Cavia porcellus (domestic guinea pig)	EC50 (µMol)	50.0000	0.0026	0.5334	1.2020	AID86857
RNA-directed RNA polymerase		EC50 (µMol)	50.0000	0.0018	0.2348	2.8000	AID86857
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID46752	The cytotoxicity against CEM cells	1997	Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17	Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl) purine nucleosides.
AID218762	Antiviral activity against Influenza virus (A/Sweden/3/50/ (H1N1)) in dog kidney (MDCK) cells expressed.	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Purine 2'-deoxy-2'-fluororibosides as antiinfluenza virus agents.
AID1204708	Inhibition of RSV A2 RNA-dependent RNA polymerase expressed in human Hep2 cells using ATP, GTP, UTP, CTP and 1.5 uCi [alpha-32P] NTP as substrate assessed as reduction of total radiolabled transcript after 90 mins by agarose gel electrophoresis	2015	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12	Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID86377	The cytotoxicity against HepG2 2.2.15 cells expressed as IC50	1997	Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17	Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl) purine nucleosides.
AID1204707	Antiviral activity against RSV A2 infected in human Hep2 cells assessed as protection against virus-induced cytopathic effect after 4 days by Cell-Titer Glo assay	2015	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12	Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID86858	Inhibition HCV NS5B-mediated RNA synthesis	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID1204710	Inhibition of human mitochondrial DNA polymerase gamma large subunit/DNA polymerase gamma accessory subunit using 32P-D19/D36 as DNA primer/template assessed as single nucleotide incorporation rate at 100 uM after 5 to 90 mins by PAGE analysis relative to	2015	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12	Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID1204709	Inhibition of human mitochondrial RNA polymerase using 5'-32P-R12/D18 as RNA/DNA template assessed as single nucleotide incorporation rate at 500 uM after 0.17 to 30 mins by PAGE analysis	2015	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12	Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID750143	Inhibition of HCV 1b NS5b polymerase	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Evaluation of 2'-α-fluorine modified nucleoside phosphonates as potential inhibitors of HCV polymerase.
AID86373	compound was tested in vitro for anti HBV activity in HepG2 2.2.15 cells	1997	Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17	Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl) purine nucleosides.
AID662565	Growth inhibition of Trichomonas vaginalis T1 at 100 uM after 24 hrs by hemocytometry	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	S-Adenosylhomocysteine hydrolase of the protozoan parasite Trichomonas vaginalis: potent inhibitory activity of 9-(2-deoxy-2-fluoro-β,D-arabinofuranosyl)adenine.
AID662566	Growth inhibition of Trichomonas vaginalis T1 after 24 hrs by hemocytometry	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	S-Adenosylhomocysteine hydrolase of the protozoan parasite Trichomonas vaginalis: potent inhibitory activity of 9-(2-deoxy-2-fluoro-β,D-arabinofuranosyl)adenine.
AID218763	Cytotoxicity in uninfected dog kidney (MDCK) cells.	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Purine 2'-deoxy-2'-fluororibosides as antiinfluenza virus agents.
AID86857	Inhibition HCV RNA replication	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	6 (20.00)	18.7374
1990's	5 (16.67)	18.2507
2000's	10 (33.33)	29.6817
2010's	7 (23.33)	24.3611
2020's	2 (6.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	30 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	7.43	2	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycine [no description available]	2.02	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
purine 1H-purine : The 1H-tautomer of purine.. 3H-purine : The 3H-tautomer of purine.. 9H-purine : The 9H-tautomer of purine.. 7H-purine : The 7H-tautomer of purine.	2.21	1	purine
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	1.96	1	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
hydroxyurea [no description available]	2.37	2	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	7.47	2	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
fluoroacetic acid fluoroacetic acid: N1 same as NM; RN given refers to parent cpd. fluoroacetic acid : A haloacetic acid that is acetic acid in which one of the methyl hydrogens is substituted by fluorine.	2.01	1	haloacetic acid; organofluorine compound	EC 4.2.1.3 (aconitate hydratase) inhibitor
thymidine [no description available]	1.96	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
uridine [no description available]	1.96	1	uridines	drug metabolite; fundamental metabolite; human metabolite
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	2	1	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.02	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.02	1	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
cytidine [no description available]	1.96	1	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.	2.01	1	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cordycepin [no description available]	2.44	2	3'-deoxyribonucleoside; adenosines	antimetabolite; nucleoside antibiotic
dimethyl sulfate dimethyl sulfate: RN given refers to unlabeled cpd; structure. dimethyl sulfate : The dimethyl ester of sulfuric acid.	2	1	alkyl sulfate	alkylating agent; immunosuppressive agent
thiazoles [no description available]	2.05	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
toyocamycin Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.	7.05	1	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; nitrile; ribonucleoside	antimetabolite; antineoplastic agent; apoptosis inducer; bacterial metabolite
2-fluoroadenine 2-fluoroadenine : An organofluorine compound that is adenine in which the hydrogen at position 2 (the carbon between the two nitrogens of the pyrimidine ring) is replaced by a fluorine.	7.05	1	organofluorine compound; purines	antineoplastic agent
deoxycytidine [no description available]	1.96	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2'-deoxyadenosine 2'-deoxyformycin A: RN not in Chemline 9/85; RN and structure given in first source	2.71	3	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cladribine [no description available]	1.96	1	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	3.09	5	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	2.48	2	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
fluorides [no description available]	2.41	2	halide anion; monoatomic fluorine
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	7.05	1	benzamides; carboxylic ester
fialuridine [no description available]	2.11	1
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.4	2	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
2-aminoadenosine [no description available]	2.07	1	purine nucleoside
adenosine 2',3'-ribo-epoxide adenosine 2',3'-ribo-epoxide: structure	2.07	1
2'-fluoro-2'-deoxycytidine [no description available]	2.5	2
2'-o-methyladenosine cordysinin B : A member of the class of adenosines that is adenosine in which the hydroxy group at position 2' is replaced by a methoxy group. It has been isolated from the mycelia of Cordyceps sinensis.	2.02	1	adenosines; ether	fungal metabolite
3'-fluoro-3'-deoxyadenosine 3'-fluoro-3'-deoxyadenosine: structure given in first source	2.44	2
5'-deoxy-5'-s-isobutylthioadenosine 5'-deoxy-5'-S-isobutylthioadenosine: considered an analog of S-adenosylhomocysteine; structure	2.07	1
4-fluorothreonine 4-fluorothreonine: from Streptomyces cattleya	2.01	1	amino acid zwitterion; fluoroamino acid; L-threonine derivative; non-proteinogenic L-alpha-amino acid
2'fluoro-2'-deoxyuridine [no description available]	2.5	2
2'-deoxyaristeromycin [no description available]	2.4	2
2,3-dihydro-1h-imidazo(1,2-b)pyrazole 2,3-dihydro-1H-imidazo(1,2-b)pyrazole: inhibitor of DNA synthesis	2.37	2
5'-methylthioadenosine 5'-methylthioadenosine: structure. 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group.	1.97	1	thioadenosine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
3'-c-methyladenosine 3'-C-methyladenosine: structure in first source	2.02	1
2'-c-methyladenosine 2'-C-methyladenosine: antiviral	2.02	1
fludarabine [no description available]	2.67	3	purine nucleoside
sodium borohydride sodium borohydride: RN given refers to parent cpd	2	1	inorganic sodium salt; metal tetrahydridoborate
5'-chloro-5'-deoxyadenosine [no description available]	2.07	1	adenosines
2'-amino-2'-deoxyuridine 2'-amino-2'-deoxyuridine: structure in first source	2.07	1
4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone: structure	1.96	1
5'-amino-5'-deoxyadenosine [no description available]	2.07	1
balapiravir balapiravir: a prodrug of R1479; structure in first source	2.11	1
oligonucleotides [no description available]	2.36	2
s-adenosylmethionine (R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.	2.99	4	organic cation; sulfonium compound	coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
deoxyguanosine [no description available]	2.39	2	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanine [no description available]	2.01	1	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
inosine [no description available]	2.07	1	inosines; purines D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2'-o-methylguanosine 2'-O-methylguanosine : Guanosine with the hydrogen on the hydroxyl at position C-2' substituted with a methyl group.	2.02	1	methylguanosine	metabolite
2'-deoxy-2'-fluoroguanosine 2'-deoxy-2'-fluoroguanosine: has activity in human respiratory epithelial cells against both influenza A & B viruses	2.46	2
8-hydroxy-2'-deoxyguanosine 8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.	2.01	1	guanosines	biomarker
3-deoxyguanosine 3'-deoxyguanosine : A 3'-deoxyribonucleoside having guanine as the nucleobase.	2.02	1	3'-deoxyribonucleoside; guanosines	EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
formycins Formycins: Pyrazolopyrimidine ribonucleosides isolated from Nocardia interforma. They are antineoplastic antibiotics with cytostatic properties.	2.4	2

Condition	Relationship Strength	Studies
Trichomoniasis, Human [description not available]	2.05	1
Trichomonas Vaginitis Inflammation of the vagina, marked by a purulent discharge. This disease is caused by the protozoan TRICHOMONAS VAGINALIS.	2.05	1
Glial Cell Tumors [description not available]	2.01	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.01	1
Adenomatous Polyposis Coli, Familial [description not available]	2.01	1
Colorectal Cancer [description not available]	2.01	1
Adenomatous Polyposis Coli A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.	2.01	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.01	1
Leukemia L 1210 [description not available]	2.37	2
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.01	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.01	1
Acute Myelogenous Leukemia [description not available]	1.97	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1.97	1

2'-fluoro-2'-deoxyadenosine

Cross-References

Synonyms (33)

Research Excerpts

Dosage Studied

Protein Targets (2)

Inhibition Measurements

Activation Measurements

Ceullar Components (1)

Bioassays (14)

Research

Studies (30)

Market Indicators

Research Demand Index: 18.79

Study Types

2'-fluoro-2'-deoxyadenosine

Cross-References

Synonyms (33)

Research Excerpts

Dosage Studied

Protein Targets (2)

Inhibition Measurements

Activation Measurements

Ceullar Components (1)

Bioassays (14)

Research

Studies (30)

Market Indicators

Research Demand Index: 18.79

Study Types

Related Drugs (58)

Related Conditions (13)